Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $34.00 USD
Change Today -0.17 / -0.50%
Volume 6.8K
MKGAY On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa-unsponsored adr (MKGAY) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - $39.43
52 Week Low
08/12/14 - $27.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

merck kgaa-unsponsored adr (MKGAY) Related Businessweek News

No Related Businessweek News Found

merck kgaa-unsponsored adr (MKGAY) Details

Merck Kommanditgesellschaft auf Aktien discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. The company provides pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases; fertility drugs for every stage of the reproductive cycle; hypoallergenic products for specific immunotherapy and diagnosis of type 1 allergies; and biosimilars focusing on oncology and inflammatory disorders. It also manufactures and markets over-the-counter pharmaceuticals to address mobility, women’s and children’s health, cough and cold, and everyday health protection under the Neurobion, Bion, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brand names. In addition, the company offers life science tools and technologies for use in the research, development, and manufacture of biotechnological and pharmaceutical drug therapies, as well as in research and application laboratories. Further, it provides specialty chemicals that are used in various end products, including liquid crystals for displays; LED materials for lighting, as well as organic light-emitting diode materials for lighting and displays; functional materials for solar panels and energy solutions; effect pigments, as well as active ingredients and fillers for cosmetics, food, and pharmaceutical products; pigments and functional materials for coatings, printing, and plastics; and specialty chemical materials for the electronics industry. Merck Kommanditgesellschaft auf Aktien was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

39,842 Employees
Last Reported Date: 05/19/15
Founded in 1668

merck kgaa-unsponsored adr (MKGAY) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €6.6M
Group Chief Financial Officer and Member of E...
Total Annual Compensation: €1.2M
Chief Executive Officer of Life Science & Per...
Total Annual Compensation: €4.7M
Vice Chairman of Executive Board and Deputy C...
Total Annual Compensation: €6.0M
Head of Group Human Resources, General Partne...
Total Annual Compensation: €4.0M
Compensation as of Fiscal Year 2014.

merck kgaa-unsponsored adr (MKGAY) Key Developments

Merck KGaA Receives CE Mark Approval for Gavi and Geri Fertility Technologies

Merck KGaA has received CE mark approval for the two new advanced fertility technologies Gavi and Geri, allowing to market the technologies in the European Union. Recently, Merck signed a global collaboration agreement with Genea Biomedx that manufactures both products. The agreement provided Merck global marketing and commercialization rights to Genea's product portfolio.

Merck KGaA, Illumina Inc. and Genea Limited Announce Formation of Global Fertility Alliance

Merck KGaA announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. The alliance is a partnership between the biopharmaceutical business of Merck, Illumina Inc. and Genea Limited. The alliance aims to improve the consistency in ART worldwide and addresses the need for more standardization of fertility processes within the ART laboratory. The three companies will launch their initiative at the 31st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Lisbon, Portugal, on 13 June 2015. This is another important step for the biopharmaceuticals business of Merck, KGaA, towards establishing global standards in the growing market of fertility technologies and the ultimate goal of helping families to have a baby. With the establishment of the alliance, the biopharmaceuticals business of Merck, KGaA, Illumina and Genea emphasize their desire to help improve fertility outcomes by contributing to the standardization of technologies and protocols in ART labs. Currently, variation in practices and techniques can lead to inconsistent results and outcomes. Recognizing the importance of innovation in ART technologies the alliance aims to enhance progress and innovation in three ways: Firstly, the founding members aim to foster integration of multiple, leading fertility technologies. Secondly, building on this, the alliance will aim to collaborate with leading health care professionals and medical societies to develop global standards. And finally, as technologies in the fertility space are rapidly advancing, the alliance will also develop educational resources for health care professionals worldwide. These efforts will include training curricula and workshops as well as access to model labs, symposia and events at medical meetings.

Merck KGaA Announces Global Collaboration Agreement with Genea Biomedx

Merck KGaA announced a global collaboration agreement with Genea Biomedx. With this partnership, Merck KGaA receives global marketing and commercialization rights to Genea Biomedx's product portfolio. This comprises Gavi, Geri and Gems product lines for use in the IVF laboratories which are expected to receive CE mark in Europe shortly, as well as a joint development pipeline. Gavi, Geri and Gems are not cleared for use in the U.S. Gavi is a fully-automated vitrification instrument, focusing on lab processes that could reduce potential errors and possibly increase laboratory efficiency in cryopreservation of embryos and in the future for oocytes (eggs). Geri is a benchtop incubator fitted with a time-lapse camera to capture images of embryos as they develop and individually controlled incubation chambers per patient to potentially reduce disruptive events to the early-stage embryo. Gems is the latest generation of Genea's culture media for embryo cultivation. The collaboration is part of the company's strategy to continue to provide fertility solutions to its customers to increase success rates. With the global rights to these three product lines and future developments, Merck KGaA is expanding its market position, offering key potentially outcome improving technologies to support standardization, automation and objectivity. To further strengthen this position, Merck KGaA will closely collaborate with Genea Biomedx to jointly develop other innovative technology products and services, and have formed a development hub to pave the way for further improvements for the patient. The collaboration showcases both companies' commitment to improve fertility treatment. Both Merck KGaA and Genea Biomedx have a strong heritage in fertility treatment and will build on this expertise to invent and develop innovative fertility technologies. The collaboration is effective from May 1, 2015. Financial details of the agreement are not being disclosed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MKGAY:US $34.00 USD -0.17

MKGAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akzo Nobel NV €65.62 EUR +0.13
Johnson Matthey PLC 2,993 GBp -10.00
Solvay SA €122.80 EUR -1.35
UCB SA €65.58 EUR -1.09
Yara International ASA 412.50 NOK +1.40
View Industry Companies

Industry Analysis


Industry Average

Valuation MKGAY Industry Range
Price/Earnings 37.1x
Price/Sales 3.5x
Price/Book 3.0x
Price/Cash Flow 11.0x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA-UNSPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at